Resources
5 Results (showing 1 - 5)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 7/28/2021 (updated 4/2/2024)
Public health professionals refer to “hard to reach populations” as those who are not likely to access traditional health care and social services on their own due to various barriers that may include mental illness, unstable housing, lack of transportation, and substance use disorders (SUDs). Stigma and trust issues may play a role in those with SUD not seeking out services.
Posted 8/4/2021 (updated 4/2/2024)
Posted 10/20/2021 (updated 4/3/2024)
Background As the opioid overdose crisis persists and take-home naloxone (THN) programmes expand, it is important that the intervention is targeted towards those most likely to use it. We examined THN program participants to 1) describe those that return for refills, specifically those that reported multiple use (supersavers) and 2) to determine what rescuer characteristics were associated with higher rates of THN use.
Methods This study included a cohort of consenting THN recipients from June 2014- June 2021 who completed initial and refill questionnaires from a widespread program in Norway. Adjusted logistic regression was used to explore associations with higher rates of THN use. ‘Super-savers’ reported three or more THN uses.
Posted 6/14/2022 (updated 3/27/2024)
Overdose education and naloxone distribution (OEND) to laypersons are key approaches to reduce the incidence of opioid-involved overdoses. While some research has examined attitudes toward OEND, especially among pharmacists and first responders, our understanding of what laypersons believe about overdose and naloxone is surprisingly limited.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.